PD Non-Interventional Trial | NEURON23 Study - Neuron23, Inc.

A Non-interventional Study for the Collection of Biospecimens from Patients with Parkinson's Disease

Objective

This study aims to collect, analyze and preserve biospecimens from patients with LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.

Full Title

A Multi-center, Non-interventional Phase 0 Study for the Collection of Biospecimens from Patients With Parkinson's Disease.

Status

Currently Enrolling

Who may be eligible to participate?

Male or female patients, age 40 and older, who have Parkinson's Disease, and are on a stable dose of anti-Parkinson's disease medications for a minimum of 30 days prior to Day 1 of the study. Other inclusion/exclusion criteria apply.

What does participation involve?

Each subject will participate in the study for approximately 4 months and attend 4 in-clinic visits, including (1) a Screening Period of up to 21 days before the first study visit (to confirm you are suitable for the study); and (2) three (3) study visits to collect data and samples. The study visits will be on Days 1, 43, and 85 (each 6 weeks apart).

Trial Phase

Phase 0

EvergreenHealth Study ID

N23-PD-001

Principal Investigator(s)

Pinky Agarwal, MD

Clinical Trial Categories

• Parkinson's Disease

Sponsor(s)

Neuron23, Inc.

Contact

EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com